UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pten Positively Regulates Brown Adipose Function, Energy Expenditure, and Longevity

Cell metabolism, 2012-03, Vol.15 (3), p.382-394

2012

Volltextzugriff (PDF)

CDK inhibitors in cancer therapy: what is next?

Trends in pharmacological sciences (Regular ed.), 2008-01, Vol.29 (1), p.16-21

2008

Volltextzugriff (PDF)

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors

Frontiers in immunology, 2024-10, Vol.15, p.1411395

2024

Volltextzugriff (PDF)

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma

Blood, 2011-11, Vol.118 (20), p.5517-5527

2011

Volltextzugriff (PDF)

The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis

Trends in Cell Biology, 1999-11, Vol.9 (11), p.454-459

1999

Volltextzugriff (PDF)

Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases

The Journal of biological chemistry, 2009-10, Vol.284 (41), p.28392-28400

2009

Volltextzugriff (PDF)

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

Haematologica (Roma), 2010-04, Vol.95 (4), p.613-621

2010

Volltextzugriff (PDF)

Identification of novel PI3K inhibitors through a scaffold hopping strategy

Bioorganic & medicinal chemistry letters, 2017-11, Vol.27 (21), p.4794-4799

2017

Volltextzugriff (PDF)

Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway

ACS chemical biology, 2019-10, Vol.14 (10), p.2215-2223, Article acschembio.9b00525

2019

Volltextzugriff (PDF)

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

Nature structural & molecular biology, 2011-06, Vol.18 (6), p.721-727

2011

Volltextzugriff (PDF)

Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines

The Journal of biological chemistry, 2002-01, Vol.277 (1), p.550-558

2002

Volltextzugriff (PDF)

Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors

PloS one, 2012-10, Vol.7 (10), p.e45964

2012

Volltextzugriff (PDF)

Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach

Journal of medicinal chemistry, 2010-09, Vol.53 (18), p.6618-6628

2010

Volltextzugriff (PDF)

Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor

Clinical cancer research, 2022-02, Vol.28 (4), p.770-780

2022

Volltextzugriff (PDF)

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib

Journal of medicinal chemistry, 2022-10, Vol.65 (19), p.13052-13073

2022

Volltextzugriff (PDF)

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)

Journal of medicinal chemistry, 2021-01, Vol.64 (2), p.909-924

2021

Volltextzugriff (PDF)

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors

Cell chemical biology, 2021-02, Vol.28 (2), p.134-147.e14

2021

Volltextzugriff (PDF)

The STE20 Kinase HGK Is Broadly Expressed in Human Tumor Cells and Can Modulate Cellular Transformation, Invasion, and Adhesion

Molecular and Cellular Biology, 2003-03, Vol.23 (6), p.2068-2082

2003

Volltextzugriff (PDF)

Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis

Cancer research (Chicago, Ill.), 2022-07, Vol.82 (14), p.2552-2564

2022

Volltextzugriff (PDF)

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Molecular cancer therapeutics, 2021-05, Vol.20 (5), p.763-774

2021

Volltextzugriff (PDF)

Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors

European journal of medicinal chemistry, 2019-04, Vol.168, p.87-109

2019

Volltextzugriff (PDF)

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF

Life science alliance, 2022-09, Vol.5 (9), p.e202101235

2022

Volltextzugriff (PDF)

Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer

ACS medicinal chemistry letters, 2021-08, Vol.12 (8), p.1245-1252

2021

Volltextzugriff (PDF)

Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy

Bioorganic & medicinal chemistry letters, 2017-06, Vol.27 (11), p.2536-2543

2017

Volltextzugriff (PDF)

1 – 25 von 160

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(157)
Mit Volltextzugriff
(138)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(115)
Life Sciences & Biomedicine
(71)
Humans
(62)
Physical Sciences
(40)
Animals
(30)
Biological And Medical Sciences
(24)
Mice
(20)
United States
(17)
Male
(16)
Medical Sciences
(16)
Multidisciplinary Sciences
(16)
Science & Technology - Other Topics
(16)
Cell Line, Tumor
(15)
Female
(15)
Geology
(15)
Chemistry
(14)
Biochemistry & Molecular Biology
(13)
Cenozoic
(13)
Geochemistry
(13)
Mutation
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pten Positively Regulates Brown Adipose Function, Energy Expenditure, and Longevity

CDK inhibitors in cancer therapy: what is next?

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma

The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis

Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

Identification of novel PI3K inhibitors through a scaffold hopping strategy

Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines

Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors

Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach

Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors

The STE20 Kinase HGK Is Broadly Expressed in Human Tumor Cells and Can Modulate Cellular Transformation, Invasion, and Adhesion

Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF

Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer

Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy

PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases

Suchergebnisse filtern